Arix Bioscience PLC (ARIX)
Unaudited NAV for February 2023
16-March-2023 / 07:00 GMT/BST
Arix Bioscience plc
Unaudited NAV for February 2023
LONDON, 16 March 2023:Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 28 February 2023 as follows:
Date |
NAV Breakdown |
Total NAV |
NAV per share |
|||
Listed Portfolio |
Unlisted Portfolio |
Cash |
Other Interests |
|||
|
28 February 2023 (unaudited) |
£45.3m |
£57.6m |
£118.0m |
£3.1m |
£224.0m |
£1.73 |
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
Powerscourt Group
Sarah MacLeod,Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
| ISIN: | GB00BD045071 |
| Category Code: | MSCL |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 230178 |
| EQS News ID: | 1583671 |
| End of Announcement | EQS News Service |
==